[go: up one dir, main page]

GB1136039A - Improvements relating to immunosuppressive agents - Google Patents

Improvements relating to immunosuppressive agents

Info

Publication number
GB1136039A
GB1136039A GB45695/66A GB4569566A GB1136039A GB 1136039 A GB1136039 A GB 1136039A GB 45695/66 A GB45695/66 A GB 45695/66A GB 4569566 A GB4569566 A GB 4569566A GB 1136039 A GB1136039 A GB 1136039A
Authority
GB
United Kingdom
Prior art keywords
improvements relating
immunosuppressive agents
ribonuclease
oct
immunosuppressive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB45695/66A
Inventor
James Frederick Mowbray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NAT RES DEV
National Research Development Corp UK
Original Assignee
NAT RES DEV
National Research Development Corp UK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NAT RES DEV, National Research Development Corp UK filed Critical NAT RES DEV
Priority to GB45695/66A priority Critical patent/GB1136039A/en
Priority to NL6713800A priority patent/NL6713800A/xx
Priority to FR1552939D priority patent/FR1552939A/fr
Priority to FR124050A priority patent/FR7058M/fr
Priority to ES345979A priority patent/ES345979A1/en
Priority to BE705035D priority patent/BE705035A/xx
Priority to AT926367A priority patent/AT275037B/en
Publication of GB1136039A publication Critical patent/GB1136039A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1,136,039. Immunosuppressive compositions. NATIONAL RESEARCH DEVELOPMENT CORP. 3 Oct., 1967 [12 Oct., 1966], No. 45695/66. Heading A5B. [Also in Division C3] A pharmaceutical composition comprises a diluent or carrier (e.g. injectable saline) containing a compound formed from ribonuclease and a physiologically innocuous protein which may be an albumen or globulin or a second molecule of ribonuclease. The compound has immunosuppressive activity and prolongs
GB45695/66A 1966-10-12 1966-10-12 Improvements relating to immunosuppressive agents Expired GB1136039A (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GB45695/66A GB1136039A (en) 1966-10-12 1966-10-12 Improvements relating to immunosuppressive agents
NL6713800A NL6713800A (en) 1966-10-12 1967-10-11
FR1552939D FR1552939A (en) 1966-10-12 1967-10-11
FR124050A FR7058M (en) 1966-10-12 1967-10-11
ES345979A ES345979A1 (en) 1966-10-12 1967-10-11 PROCEDURE FOR THE PREPARATION OF AN ANTI-IMMUNE PROTEIN AGENT.
BE705035D BE705035A (en) 1966-10-12 1967-10-12
AT926367A AT275037B (en) 1966-10-12 1967-10-12 Process for the manufacture of agents for inhibiting immune reactions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB45695/66A GB1136039A (en) 1966-10-12 1966-10-12 Improvements relating to immunosuppressive agents

Publications (1)

Publication Number Publication Date
GB1136039A true GB1136039A (en) 1968-12-11

Family

ID=10438194

Family Applications (1)

Application Number Title Priority Date Filing Date
GB45695/66A Expired GB1136039A (en) 1966-10-12 1966-10-12 Improvements relating to immunosuppressive agents

Country Status (6)

Country Link
AT (1) AT275037B (en)
BE (1) BE705035A (en)
ES (1) ES345979A1 (en)
FR (2) FR7058M (en)
GB (1) GB1136039A (en)
NL (1) NL6713800A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4043869A (en) 1972-07-13 1977-08-23 Koch-Light Laboratories, Ltd. Water insoluble biologically active material
WO2015066550A1 (en) * 2013-10-31 2015-05-07 Resolve Therapeutics, Llc Therapeutic nuclease-albumin fusions and methods

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4043869A (en) 1972-07-13 1977-08-23 Koch-Light Laboratories, Ltd. Water insoluble biologically active material
WO2015066550A1 (en) * 2013-10-31 2015-05-07 Resolve Therapeutics, Llc Therapeutic nuclease-albumin fusions and methods
US10988745B2 (en) 2013-10-31 2021-04-27 Resolve Therapeutics, Llc Therapeutic nuclease-albumin fusions and methods
US12163165B2 (en) 2013-10-31 2024-12-10 Resolve Therapeutics, Llc Nucleic acid molecules encoding nuclease-albumin fusion proteins

Also Published As

Publication number Publication date
FR7058M (en) 1969-06-23
NL6713800A (en) 1968-04-16
AT275037B (en) 1969-10-10
FR1552939A (en) 1969-01-10
ES345979A1 (en) 1968-12-01
BE705035A (en) 1968-04-12

Similar Documents

Publication Publication Date Title
NL7714329A (en) PROCESS FOR THE PREPARATION OF 3-DE-0-METHYLFORTI-MICINS AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPONENTS AS AN ACTIVE COMPONENT.
NL7507268A (en) PROCESS FOR THE PREPARATION OF 1 (ALPHA), 24-DIHYDROXY-CHOLE-CALCIFEROLS, AS WELL AS DERIVATIVES AND PREPARATIONS THEREOF, AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPONENTS AS ACTIVE COMPONENTS.
NL7712567A (en) PROCESS FOR PREPARING TRI-SUBSTITUTED 1-PHENYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE COMPOUNDS, AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS AS AN ACTIVE COMPONENT.
GB1374824A (en) Triazolobenzodiazepines
GB1026456A (en) Improvements in or relating to methods of tedding
NL7706064A (en) PROCESS FOR THE PREPARATION OF HETEROCYCLICAL COMPOUNDS AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPONENTS AS AN ACTIVE COMPONENT.
GB1136039A (en) Improvements relating to immunosuppressive agents
CA2139518A1 (en) Antigenic regions of tlp complexes and antibodies against the same
NL7711414A (en) PROCESS FOR THE PREPARATION OF N-SUBSTITUTED LACTAMS, AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS AS AN ACTIVE COMPONENT.
NL7702180A (en) PROCESS FOR THE PREPARATION OF 9-SUBSTITUTED -8-AZAPURINS AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPONENTS AS AN ACTIVE COMPONENT.
GB1260963A (en) Substituted insulins
NL7409752A (en) PROCESS FOR PREPARING 1,4-DIGES SUBSTITUTE PIPERIDINS AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPONENTS AS ACTIVE COMPONENTS.
GB1179787A (en) Stabilised and Potentiated Therapeutic Enzyme Compositions
NL7714063A (en) PROCESS FOR THE PREPARATION OF IMIDAZOLINS AND PESTICIDE PREPARATIONS CONTAINING THESE COMPONENTS AS AN ACTIVE COMPONENT.
IE34609L (en) Therapeutic substituted thiazolidinedione
GB1051686A (en)
NL7511662A (en) PROCESS FOR THE PREPARATION OF 1-SUBSTITUTED DERIVATIVES OF 6'N-METHYL-3'-4'-DIDEOXYKANAMYCIN B, AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPONENTS AS AN ACTIVE COMPONENT.
NL7513011A (en) PROCESS FOR PREPARING 1,2,3,4-TETRAHYDROISOQINOLINS AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPONENTS AS AN ACTIVE COMPONENT.
NL7606457A (en) PROCESS FOR PREPARING 7 (BETA) -ACYLOXYCEPHALOSPORINS AND 7 (BETA) -HYDROXY INTERMEDIATE PRODUCTS AND THE PHARMACECEUTICAL PREPARATIONS CONTAINING THE FIRST COMPONENTS AS AN ACTIVE COMPONENT.
GB1339737A (en) Diagnostic agents for primary hepatoma
GB1199951A (en) Modified Dextran and Derivatives Thereof
ES2037603A1 (en) Preparations containing protease-tannin complex
GB1327930A (en) 1,4-benzodiazepine derivatives
NL7709466A (en) PROCESS FOR THE PREPARATION OF CEPHALOSPORINS, AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS AS AN ACTIVE COMPONENT.
NL7708177A (en) PROCESS FOR THE PREPARATION OF CEFEM DERIVATIVES, AND THE PHARMACEUTICAL PREPARATIONS CONTAINING THIS COMPOUND AS AN ACTIVE COMPONENT.